Tirzepatide – Technical Brief (Research Grade Compound) for Research-Use-Only.
1. Identity
Tirzepatide is a dual agonist peptide that targets GLP-1 (glucagon-like peptide-1) and GIP (glucose-dependent insulinotropic polypeptide) receptors. This mechanism enhances metabolic regulation, making it a powerful treatment for type 2 diabetes and obesity management.
2. Mechanism of Action
Tirzepatide works by:
- GLP-1 activation: Enhances insulin secretion, reduces appetite, and slows gastric emptying.
- GIP activation: Supports insulin sensitivity and metabolic balance.
3. Uses
Tirzepatide is approved for:
- Type 2 diabetes: Improves glucose control and insulin sensitivity.
- Obesity management: Helps regulate appetite and energy balance.
- Metabolic disorders: Potential applications in lipid metabolism and cardiovascular health.
4. Dosage
Standard dosing protocols include:
- Week 1–4: 2.5mg once per week.
- Week 5–8: 5mg once per week.
- Week 9+: 10mg or 15mg once per week (as tolerated).
- Administered subcutaneously (abdomen or outer thigh) using an insulin syringe.
5. Safety Profile
- Common side effects: Nausea, mild gastrointestinal discomfort, and injection site irritation.
- Precautions: Avoid use in individuals with a history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2.
- Long-term effects: Generally well-tolerated, but ongoing studies continue to assess cardiovascular benefits.
6. Storage Guidelines
- Before mixing: Store the lyophilized powder in a refrigerator (2–8°C / 36–46°F), protected from light.
- After mixing: Keep refrigerated and use within 30–45 days.
- Room temperature storage: If necessary, can be kept at up to 30°C (86°F) for a maximum of 21 days, but should not be returned to refrigeration afterward.
- Do not freeze: Freezing a reconstituted vial can degrade the peptide’s integrity.
7. Legality in the UK
Tirzepatide is approved for type 2 diabetes under the brand name Mounjaro and is available through the NHS. However, its use for weight management is still under evaluation by NICE (National Institute for Health and Care Excellence). Prescribing for obesity is currently restricted, pending further clinical data.
